BioVersys: Funding, Investors & Team (Sep 2026)
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.
BioVersys has raised $57.8M across 5 funding rounds on record, the most recent an undisclosed round of $6.1M announced in Sep 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioVersys Company Profile and Key Stats
Latest funding round on record: Sep 2024.
BioVersys Funding Rounds
BioVersys raised $4.4M in an undisclosed round announced in Jun 2021.
1 years later, a Series C of $24.7M was announced in Jun 2022.
7 months later, a Series C of $9.0M was announced in Jan 2023.
1.3 years later, a Series C of $13.6M was announced in May 2024.
4 months later, an undisclosed round of $6.1M was announced in Sep 2024.
BioVersys Founders and Leadership Team
Contact details for the BioVersys team: 1 of 1 has an email address on file.
Start 14-day free trial →BioVersys Funding Compared to Other Biotechnology Startups
BioVersys' latest round of $6.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioVersys in Biotechnology and Basel
Companies Similar to BioVersys
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
BioVersys Funding FAQs
What does BioVersys do?
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.
How much funding has BioVersys raised?
BioVersys has raised $57.8M across 5 rounds on record. The most recent is an undisclosed round of $6.1M announced in Sep 2024.
When did BioVersys last raise funding?
BioVersys' most recent funding round on record is an undisclosed round of $6.1M, announced in Sep 2024.
Who is the CEO of BioVersys?
Marc Gitzinger is listed as CEO at BioVersys.
Where is BioVersys headquartered?
BioVersys is based in Basel, Basel-Stadt, Switzerland.
How many employees does BioVersys have?
BioVersys is in the 11-50 employee band.
How does BioVersys' funding compare to other Biotechnology startups?
BioVersys' latest round of $6.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's BioVersys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioVersys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.